Please login to the form below

Not currently logged in
Email:
Password:

ertugliflozin

This page shows the latest ertugliflozin news and features for those working in and with pharma, biotech and healthcare.

The year of the blockbuster

The year of the blockbuster

Steglatro (ertugliflozin) from Pfizer and Merck:Sodium glucose co-transporter-2 (SGLT-2) inhibitors are the newest oral treatment options for diabetes, but SGLT-2 inhibitor Steglatro will be a late

Latest news

More from news
Approximately 1 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Deal Watch table for April 2013 Deal Watch table for April 2013

    60. Pfizer/ Merck &Co. Collaboration. Ertugliflozin as standalone and combination with Januvia and/or metformin for diabetes.

  • Pharma deals during April 2013 Pharma deals during April 2013

    The partnership is to co-develop and commercialise Pfizer's phase III ready oral sodium glucose co-transporter (SGLT2) inhibitor ertugliflozin for the treatment of type 2 diabetes, both as a

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...